 |
 |
| Home |
| Educational Resources |
| Patient Resources |
| External Resources |
| How can I get Involved? |
| Steering Committee |
| Meeting Minutes |
| Contact Us |
Members in Industry NetWorkMembers in Industry Articles of InterestThere has been ongoing discussion in the media and the medical literature focused on what constitutes an appropriate relationship between physicians/health care establishment and the pharmaceutical industry. Many health-care professionals have a variety of interactions with industry, perhaps by meeting with sales representatives, consulting for companies or participating on speaker bureaus, or enrolling patients in industry-sponsored clinical trials. The ACCP Members in Industry NetWork provides links to relevant articles published in peer-reviewed journals and encourages members to peruse these articles in order to stay current with issues, perspectives, and recommendations. Abbasi D, Smith R. No more free lunches. BMJ 2003; 326:1155-1156 Angell M. Is academic medicine for sale? N Engl J Med 2000; 342:1516-1518 Avorn J. Paying for drug approvals—who's using whom? N Engl J Med 2007; 356:1697-1700 Bodenheimer T. Uneasy alliance—clinical investigators and the pharmaceutical industry. N Engl J Med 2000; 342:1539-1544 Bonaccorso S, Sturchio JL. Perspectives from the pharmaceutical industry. BMJ 2003; 327:863-864 Burton B, Rowell A. Unhealthy spin. BMJ 2003; 326:1205-1207 Campbell EG. Doctors and drug companies—scrutinizing influential relationships. N Engl J Med 2007; 357:1796-1797 Campbell EG, Gruen RL, Mountford J, et al. A national survey of physician-industry relationships. N Engl J Med 2007; 356:1742-1750 (supplement included) Correspondence: N Engl J Med 2007; 357:507-508 (author reply on page 508) Campbell EG, Weissman JS, Vogeli C, et al. Financial relationships between institutional review board members and industry. N Engl J Med 2006; 355:2321-2329 Correspondence: N Engl J Med 2007; 356:965 (author reply on page 965). Campbell EG, Weissman JS, Ehringhaus S, et al. Institutional academic–industry relationships. JAMA 2007; 298:1779-1786 Choudhry NK, Stelfox HT, Detsky AS. Relationships between authors of clinical practice guidelines and the pharmaceutical industry. JAMA 2002; 287:612-617 Drug-company influence on medical education in USA. Lancet 2000; 356:781 Gelijns AC, Thier SO. Medical innovation and institutional interdependence: rethinking university-industry connections. JAMA 2002; 287:72-77 Henry D, Lexchin J. The pharmaceutical industry as a medicines provider. Lancet 2002; 360:1590-1595 Herxheimer A. Relationships between the pharmaceutical industry and patients' organizations. BMJ 2003; 326:1208-1210 Johns MM, Barnes M, Forencio, PS. Restoring balance to industry-academia relationships in an era of institutional financial conflicts of interest: promoting research while maintaining trust. JAMA 2003; 289:741-746 Lexchin J, Bero LA, Djulbegovic B, et al. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 2003; 326:1167-1170 Liberati A, Magrini N. Information from drug companies and opinion leaders. BMJ 2003; 326:1156-1157 Manheimer E, Anderson D. Survey of public information about ongoing clinical trials funded by industry: evaluation of completeness and accessibility. BMJ 2002; 325:528-531 McCarthy M. US campaign tackles drug company influence over doctors. Lancet 2007; 369:730 Melander H, Ahlqvist-Rastad J, Meijer G, et al. Evidence b(i)ased medicine—selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications. BMJ 2003; 326:1171-1173 Miller FG, Shorr AF. Ethical assessment of industry-sponsored clinical trials: a case analysis. Chest 2002; 121:1337-1342 Moynihan R. Who pays for the pizza? Redefining the relationships between doctors and drug companies. 1: Entanglement. BMJ 2003; 326:1189-1192 Moynihan R. Who pays for the pizza? Redefining the relationships between doctors and drug companies. 2: Disentanglement. BMJ 2003; 326:1193-1196 Nabel EG. Conflict of interest—or conflict of priorities? N Engl J Med 2006; 355:2365-2367 Singh D. Drug companies advised to publish unfavourable trial results. BMJ 2003; 326:1163 Smith R. Medical journals and pharmaceutical companies: uneasy bedfellows. BMJ 2003; 325:1202-1205 Somerset M, Weiss M, Fahey T. Dramaturgical study of meetings between general practitioners and representatives of pharmaceutical companies. BMJ 2001; 323:1481-1484 Tillotson GS. Implementation and physician behavior change: an industry perspective. Chest 2000; 118(suppl):59S-61S Wager E. How to dance with porcupines: rules and guidelines on doctors' relations with drug companies. BMJ 2003; 326:1196-1198 Watkins C, Moore L, Harvey I, et al. Characteristics of general practitioners who frequently see drug industry representatives: national cross sectional study. BMJ 2003; 326:1178-1179 |
 |
||
|
||
|
||
|
||
|